PT  - JOURNAL ARTICLE
AU  - Meyer, Arne
AU  - Vuorinen, Anna
AU  - Zielinska, Agnieszka E.
AU  - Strajhar, Petra
AU  - Lavery, Gareth G.
AU  - Schuster, Daniela
AU  - Odermatt, Alex
TI  - Formation of Threohydrobupropion from Bupropion Is Dependent on 11<em>β</em>-Hydroxysteroid Dehydrogenase 1
AID  - 10.1124/dmd.113.052936
DP  - 2013 Sep 01
TA  - Drug Metabolism and Disposition
PG  - 1671--1678
VI  - 41
IP  - 9
4099  - http://dmd.aspetjournals.org/content/41/9/1671.short
4100  - http://dmd.aspetjournals.org/content/41/9/1671.full
SO  - Drug Metab Dispos2013 Sep 01; 41
AB  - Bupropion is widely used for treatment of depression and as a smoking-cessation drug. Despite more than 20 years of therapeutic use, its metabolism is not fully understood. While CYP2B6 is known to form hydroxybupropion, the enzyme(s) generating erythro- and threohydrobupropion have long remained unclear. Previous experiments using microsomal preparations and the nonspecific inhibitor glycyrrhetinic acid suggested a role for 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) in the formation of both erythro- and threohydrobupropion. 11β-HSD1 catalyzes the conversion of inactive glucocorticoids (cortisone, prednisone) to their active forms (cortisol, prednisolone). Moreover, it accepts several other substrates. Here, we used for the first time recombinant 11β-HSD1 to assess its role in the carbonyl reduction of bupropion. Furthermore, we applied human, rat, and mouse liver microsomes and a selective inhibitor to characterize species-specific differences and to estimate the relative contribution of 11β-HSD1 to bupropion metabolism. The results revealed 11β-HSD1 as the major enzyme responsible for threohydrobupropion formation. The reaction was stereoselective and no erythrohydrobupropion was formed. Human liver microsomes showed 10 and 80 times higher activity than rat and mouse liver microsomes, respectively. The formation of erythrohydrobupropion was not altered in experiments with microsomes from 11β-HSD1-deficient mice or upon incubation with 11β-HSD1 inhibitor, indicating the existence of another carbonyl reductase that generates erythrohydrobupropion. Molecular docking supported the experimental findings and suggested that 11β-HSD1 selectively converts R-bupropion to threohydrobupropion. Enzyme inhibition experiments suggested that exposure to bupropion is not likely to impair 11β-HSD1-dependent glucocorticoid activation but that pharmacological administration of cortisone or prednisone may inhibit 11β-HSD1-dependent bupropion metabolism.